GlassScriptPhysician profile
Victor G Gian
NPI 1205878402
$47,559.24
in general payments reported to CMS, 2019-2025
65 companies · $6,065 in 2025
The $6,065 reported for 2025 was more than what 76% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $4,459 · 2021: $1,871 · 2022: $2,271 · 2023: $793 · 2024: $5,936 · 2025: $6,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,423 · Food and Beverage: $4,282 · Education: $89.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,422.50 |
| Food and Beverage | $4,281.71 |
| Education | $89.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $25,427.89 | 2019-2023 | Xgeva, Vectibix, Nplate |
| Karyopharm Therapeutics INC. | $5,284.13 | 2020-2021 | |
| Beigene USA, INC. | $3,365.21 | 2023-2025 | Brukinsa, Tevimbra |
| Glaxosmithkline, LLC. | $3,027.46 | 2022-2025 | Ojjaara, Zejula, Jemperli |
| Array Biopharma INC | $1,985.98 | 2019-2024 | Bosulif, Ibrance, Braftovi |
| Astrazeneca Pharmaceuticals LP | $1,815.47 | 2019-2025 | Tagrisso, Enhertu, Calquence |
| Janssen Biotech, INC. | $1,094.32 | 2019-2025 | Darzalex, Imbruvica, Tecvayli |
| Novartis Pharmaceuticals Corporation | $562.84 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $338.55 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| E.R. Squibb & Sons, L.L.C. | $323.71 | 2019-2025 | Opdivo, Abilify, Opdualag |
| Celgene Corporation | $295.27 | 2020-2025 | Reblozyl, Pomalyst, Opdualag |
| Astellas Pharma US INC | $274.89 | 2019-2025 | Xtandi, Padcev, Vyloy |
| Regeneron Healthcare Solutions, INC. | $254.80 | 2019-2025 | Libtayo |
| Heron Therapeutics, INC. | $194.20 | 2022 | |
| Genentech USA, INC. | $180.65 | 2019-2020 |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $175.36 | 2019-2025 | Monjuvi, Pemazyre, Zynyz |
| Daiichi Sankyo INC. | $162.70 | 2023-2025 | Enhertu, Datroway |
| Genzyme Corporation | $158.58 | 2019-2025 | |
| Eisai INC. | $154.92 | 2019-2025 | |
| Abbvie INC. | $149.22 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $147.05 | 2019-2025 | |
| Eagle Pharmaceuticals, INC. | $125.12 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $115.54 | 2019-2025 | Onivyde |
| Pfizer INC. | $109.39 | 2019-2025 | |
| Aveo Pharmaceuticals, INC. | $107.47 | 2023-2025 | Fotivda |
| Mirati Therapeutics, INC. | $102.76 | 2023-2024 | Krazati |
| Puma Biotechnology, INC. | $96.70 | 2024-2025 | |
| Exelixis INC. | $90.83 | 2020-2025 | Cabometyx |
| Takeda Pharmaceuticals U.S.A., INC. | $90.53 | 2019-2025 | Ninlaro, Iclusig, Fruzaqla |
| Jazz Pharmaceuticals INC. | $84.66 | 2019-2025 | |
| Tersera Therapeutics LLC | $84.36 | 2023-2025 | Zoladex, Xermelo |
| Alexion Pharmaceuticals, INC. | $77.84 | 2019-2024 | Ultomiris |
| Deciphera Pharmaceuticals INC. | $74.57 | 2024-2025 | Qinlock, Romvimza |
| Genmab U.S., INC. | $72.66 | 2024-2025 | Epkinly |
| Lilly USA, LLC | $71.66 | 2020-2025 | Jaypirca, Verzenio, Retevmo |
| Gilead Sciences, INC. | $71.64 | 2019-2023 | Trodelvy |
| Taiho Oncology, INC. | $63.63 | 2019-2025 | |
| Adc Therapeutics America, INC. | $60.27 | 2022-2025 | |
| Pharmaessentia USA Corporation | $52.32 | 2025 | Besremi |
| Iovance Biotherapeutics, INC. | $50.30 | 2025 | Amtagvi |
| Agios Pharmaceuticals, INC. | $43.06 | 2025 | Pyrukynd |
| Sun Pharmaceutical Industries INC. | $38.35 | 2024-2025 | |
| Legend Biotech USA INC. | $36.68 | 2025 | Carvykti |
| Emd Serono, INC. | $36.54 | 2019-2024 | |
| Rigel Pharmaceuticals, INC. | $35.99 | 2020-2025 | Tavalisse, Rezlidhia, Gavreto |
| Kite Pharma, INC. | $33.73 | 2023 | Yescarta |
| Morphosys, US INC. | $30.94 | 2023 | Monjuvi |
| Teva Pharmaceuticals USA, INC. | $27.60 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.10 | 2025 | Gilotrif |
| Blueprint Medicines Corporation | $24.52 | 2024 | Ayvakit |
| Servier Pharmaceuticals LLC | $21.46 | 2025 | |
| Dova Pharmaceuticals | $21.08 | 2020 | |
| Biocompatibles, INC. | $20.65 | 2019 | |
| Geron Corporation | $20.42 | 2025 | Rytelo |
| Stemline Therapeutics INC. | $17.39 | 2025 | Orserdu |
| Pharmacosmos Therapeutics INC. | $17.13 | 2025 | Monoferric |
| Partner Therapeutics, INC. | $16.68 | 2020 | |
| Coherus Oncology, INC. | $16.47 | 2025 | Loqtorzi |
| Clovis Oncology, INC. | $15.72 | 2019 | |
| Cti Biopharma Corp. | $15.37 | 2023 | Vonjo |
| Cycle Pharmaceuticals INC | $15.36 | 2025 | Phyrago |
| Sumitomo Pharma America, INC. | $14.35 | 2024 | Orgovyx |
| Sobi, INC | $13.92 | 2025 | |
| Foundation Medicine, INC. | $12.98 | 2019 | |
| Seagen INC. | $11.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Gian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.